799
Views
0
CrossRef citations to date
0
Altmetric
Clinical Study

Association between MPO-463G > A polymorphism and chronic kidney disease: a meta-analysis

, , , &
Pages 541-546 | Received 31 Jul 2017, Accepted 06 Mar 2018, Published online: 03 Oct 2018

References

  • Strzepa A, Pritchard KA, Dittel BN. Myeloperoxidase: a new player in autoimmunity. Cell Immunol. 2017;317:1–8.
  • Kisic B, Miric D, Dragojevic I, et al. Role of myeloperoxidase in patients with chronic kidney disease. Oxid Med Cell Longev. 2016;2016:1069743.
  • Rutgers A, Heeringa P, Kooman JP, et al. Peripheral blood myeloperoxidase activity increases during hemodialysis. Kidney Int. 2003;64:760.
  • Piedrafita FJ, Molander RB, Vansant G, et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412–14420.
  • Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; [cited 2017 June 21]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf
  • Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–1012.
  • Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
  • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
  • Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
  • Buraczynska K, Koziol-Montewka M, Majdan M, et al. Polymorphisms of tumor necrosis factor and myeloperoxidase genes in patients with chronic renal failure on peritoneal dialysis. Mol Diagn. 2003;7:175–180.
  • Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl. 2003;63:S172–S176.
  • Krajewska M, Kościelska-Kasprzak K, Weyde W, et al. Impact of donor-dependent genetic factors on long-term renal graft function. Transplant Proc. 2009;41:2978–2980.
  • Krajewska M, Kościelska-Kasprzak K, Weyde W, et al. Recipient genetic determinants of inflammatory process and nonstandard atherosclerosis risk factors affect kidney graft function early posttransplantation. Transplant Proc. 2009;41:3060–3062.
  • Katakami N, Kume S, Kaneto H, et al. Association of myeloperoxidase G-463A gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic subjects. Endocr J. 2013;60:457–471.
  • Grahl DA, Axelsson J, Nordfors L, et al. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. Blood Purif. 2007;25:210–218.
  • Buraczynska K, Koziol-Montewka M, Majdan M, et al. Genetic determination of TNF and myeloperoxidase production in dialyzed patients with diabetic nephropathy. Ren Fail. 2004;26:633–639.
  • Bouali H, Nietert P, Nowling TM, et al. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol. 2007;34:2028–2034.
  • Doi K, Noiri E, Maeda R, et al. Functional polymorphism of the myeloperoxidase gene in hypertensive nephrosclerosis dialysis patients. Hypertens Res. 2007;30:1193–1198.
  • Debadwar S, Sharma S, Sikka M, et al. Assessment of myeloperoxidase (MPO) gene polymorphism in patients with chronic kidney Disease (CKD). Indian J Hematol Blood Transfus. 2016;32:S400.
  • Magidson J. Correlated component regression: re-thinking regression in the presence of near collinearity. Vol. 56. New York: Springer ; 2013. p. 65–78.